Assenagon Asset Management S.A. boosted its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) by 651.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 187,490 shares of the biopharmaceutical company's stock after buying an additional 162,531 shares during the period. Assenagon Asset Management S.A. owned approximately 0.42% of Puma Biotechnology worth $534,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Running Point Capital Advisors LLC bought a new stake in Puma Biotechnology during the first quarter valued at $29,000. Mackenzie Financial Corp purchased a new stake in Puma Biotechnology during the first quarter valued at about $35,000. Mirabella Financial Services LLP purchased a new stake in Puma Biotechnology during the first quarter valued at about $73,000. UBS Group AG raised its position in Puma Biotechnology by 48.8% during the first quarter. UBS Group AG now owns 25,985 shares of the biopharmaceutical company's stock valued at $75,000 after purchasing an additional 8,523 shares in the last quarter. Finally, Pitcairn Co. purchased a new stake in Puma Biotechnology during the first quarter valued at about $79,000. Institutional investors own 62.26% of the company's stock.
Get Puma Biotechnology alerts:Insider Transactions at Puma Biotechnology
In other news, Director Michael Patrick Miller sold 25,000 shares of Puma Biotechnology stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $3.55, for a total value of $88,750.00. Following the transaction, the director now owns 54,858 shares in the company, valued at $194,745.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 28,697 shares of company stock worth $98,411. Company insiders own 21.20% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have weighed in on PBYI. HC Wainwright lowered their price target on Puma Biotechnology from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, August 5th. StockNews.com began coverage on Puma Biotechnology in a research report on Wednesday, October 12th. They set a "buy" rating on the stock.Puma Biotechnology Stock Up 2.3 %
PBYI opened at $2.20 on Friday. The company has a market cap of $100.23 million, a P/E ratio of -2.56 and a beta of 0.65. The business's 50-day moving average price is $2.60 and its 200-day moving average price is $2.66. The company has a current ratio of 2.01, a quick ratio of 1.89 and a debt-to-equity ratio of 4.95. Puma Biotechnology, Inc. has a 12 month low of $1.60 and a 12 month high of $6.76.
Puma Biotechnology (NASDAQ:PBYI – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.02 by $0.19. The firm had revenue of $59.50 million for the quarter, compared to the consensus estimate of $53.20 million. Puma Biotechnology had a negative return on equity of 1,021.09% and a negative net margin of 16.68%. On average, equities analysts expect that Puma Biotechnology, Inc. will post -0.06 EPS for the current year.
Puma Biotechnology Company Profile
(Get Rating)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.
See Also
- Get a free copy of the StockNews.com research report on Puma Biotechnology (PBYI)
- Should Investors Raise a Glass to Boston Beer Company?
- MarketBeat: Week in Review 10/17-10/21
- American Express Beats Earnings & Revenue Views, Raises Guidance
- The Institutions Spin Whirlpool Into Bargain Basement Territory
- Snap Stock Falls As User Growth Slows To Single-Digits
Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating).
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.